Teachers Retirement System of The State of Kentucky Grows Holdings in TransMedics Group, Inc. $TMDX

Teachers Retirement System of The State of Kentucky grew its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 97.0% in the first quarter, HoldingsChannel reports. The fund owned 16,779 shares of the company’s stock after acquiring an additional 8,260 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in TransMedics Group were worth $1,668,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Global Assets Advisory LLC acquired a new stake in shares of TransMedics Group during the 1st quarter valued at about $186,000. Fifth Third Bancorp raised its holdings in TransMedics Group by 4,638.5% in the 1st quarter. Fifth Third Bancorp now owns 20,802 shares of the company’s stock worth $2,068,000 after purchasing an additional 20,363 shares during the period. Candriam S.C.A. boosted its position in TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after purchasing an additional 49,580 shares in the last quarter. Integrated Advisors Network LLC acquired a new stake in TransMedics Group in the first quarter valued at approximately $4,731,000. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in TransMedics Group by 95.0% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock valued at $45,000 after purchasing an additional 207 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Stifel Nicolaus upped their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research note on Thursday, June 18th. Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Finally, Piper Sandler decreased their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Hold” and an average price target of $134.50.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $75.38 on Thursday. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The firm has a market capitalization of $2.61 billion, a PE ratio of 17.13 and a beta of 1.89. The business’s 50 day moving average price is $70.66 and its 200-day moving average price is $105.14.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.70 earnings per share. As a group, equities research analysts expect that TransMedics Group, Inc. will post 1.92 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.